Clinical-stage immunotherapy development in oncology and infectious disease.
Paid company reports are visibly labeled. Each report identifies whether its link is an original announcement, primary filing or secondary source. Independent editorial reporting, when published, is identified separately.
BioVaxys Technology Corp. reported positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer.
Read full report →BioVaxys reported positive preliminary results from the investigator-initiated Phase 1B/2 PESCO study in recurrent epithelial ovarian cancer.
Read full report →Share your latest release, filing or company milestone with our team. We’ll review the story and discuss the right coverage and distribution approach for your company.
